Brought to you by 
Series C brings in €20.3mm in equity, €5mm in debt for Promethera; adds €10mm
28 Oct 2016
Executive Summary
Promethera Biosciences SA NV, developer of the Promethera HepaStem cell therapy for treating inborn errors of metabolism and acquired liver diseases, raised €20.3mm ($25.2mm) in its Series C financing led by Vesalius Biocapital and Boehringer Ingelheim Venture Fund, which were joined by other returning backers Société Régionale d'Investissement de Wallonie, Shire, Mitsui Global Investment, Vives-Louvain Technology Transfer Office Fund, and business angels, and new investors SFPI-FPIM and SMS Investments. In addition, Promethera received €5mm in debt funding from the Walloon Region. The financing will support ongoing clinical development of Promethera HepaStem, which recently completed Phase I/II.
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Drug Discovery Tools
- Gene Therapy, Cell Therapy
Deal Status
- Final
Deal Type
-
Financing
- Venture Financing
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Series C brings in €20.3mm in equity, €5mm in debt for Promethera; adds €10mm
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice